The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Name on ClinicalTrials.gov (link is external) | Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients |
|---|---|
| Study Drug | QBW251 |
| Type of Study Drug | CFTR Modulation |
| Study Title | A randomized, double blind placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and preliminary pharmacodynamics of single and multiple ascending doses of QBW251 in healthy subjects and multiple doses in cystic fibrosis patients |
| Study Phase | 2 |
| Study Sponsor | Novartis |
http://clinicaltrials.gov/ct2/show/study/NCT02190604 (link is external) | |
| Participating ECFS-CTN sites | France: Lyon, Montpellier, West-Paris(Cochin) Germany : Berlin, Cologne Italy: Florence, Genoa, Milan, Rome, Verona The Netherlands: Utrecht UK: Belfast, London |
| Age | 18 Years to 55 Years |